1065 terminated. 1065 Phase 2, 160 Phase 1, 115 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1065 | Terminated 1065 |
| Phase 1 | 160 | Terminated 160 |
| Phase 3 | 115 | Terminated 115 |
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2025-12-19 | 2026-05-22 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2025-10-28 | 2026-08-07 |
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis BGB-45035, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | BeiGene | 49 | 2025-08-21 | 2026-05-28 |
| An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | Phase 2 | Terminated | Tisento Therapeutics | 37 | 2025-08-18 | 2026-10-30 |
| A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS) STR04 - Amyotrophic Lateral Sclerosis | Phase 2 | Terminated | New England Cell Therapeutics, Inc. | 1 | 2025-08-12 | 2025-12-18 |
| Extension Study of Participants From SPG302-ALS-001 SPG302 - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Terminated | Spinogenix | 16 | 2025-05-29 | 2025-12-17 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NVG-2089 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Nuvig Therapeutics, Inc. | 14 | 2025-04-25 | 2026-10-06 |
| Extension Study of Participants From SPG302-ALZ-101 SPG302 - Alzheimer's Disease | Phase 2 | Terminated | Spinogenix | 12 | 2025-03-25 | 2025-12-18 |
| A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease VENT-02, Placebo - Parkinson Disease | Phase 1 / Phase 2 | Terminated | Ventus Therapeutics U.S., Inc. | 29 | 2025-03-05 | 2025-10-29 |
| Study of the Oral Treatment MTR-601 in Cervical Dystonia MTR-601, Placebo - Cervical Dystonia | Phase 2 | Terminated | Motric Bio | 38 | 2025-02-28 | 2026-09-17 |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) MK-1167, Placebo - Alzheimer Disease, Dementia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 369 | 2024-12-16 | 2026-07-01 |
| Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) Guanfacine Hydrochloride Immediate Release, Placebo - Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome | Phase 2 | Terminated | Rachel G. Greenberg, MD, MB, MHS | 3 | 2024-12-09 | 2026-04-17 |
| A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) ARGX-119, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Terminated | argenx | 60 | 2024-10-23 | 2026-09-15 |
| Study of ASN51 in Adults With Early Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 2 | Terminated | Asceneuron S.A. | 123 | 2024-10-16 | 2025-06-29 |
| The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain OK-101 0.05%, OK-101 0.1%, Placebo - Neuropathic Pain | Phase 2 | Terminated | Okyo Pharma Ltd | 18 | 2024-10-15 | 2025-08-15 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| BHV-7000 Open-Label Extension Bipolar Mania Study BHV-7000 - Bipolar Disorder | Phase 2 | Terminated | Biohaven Therapeutics Ltd. | 94 | 2024-06-24 | 2025-12-16 |
Showing 20 of 1065. Sign in to see all of them.
Brain Neoplasms (117) · Alzheimer Disease (84) · Stroke (60) · Multiple Sclerosis (50) · Glioblastoma (49) · Parkinson Disease (48) · Ischemic Stroke (33) · Neuralgia (33) · Glioma (31) · Pain (28) · Amyotrophic Lateral Sclerosis (26) · Muscular Dystrophy, Duchenne (26) · Central Nervous System Neoplasms (24) · Epilepsy (24) · Astrocytoma (23)
Central Nervous System Diseases (644) · Brain Diseases (566) · Pathological Conditions, Signs and Symptoms (334) · Signs and Symptoms (241) · Neurodegenerative Diseases (234) · Neurologic Manifestations (231) · Neuromuscular Diseases (213) · Neoplasms (208) · Neoplasms by Site (188) · Nervous System Neoplasms (186) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (169) · Mental Disorders (160) · Genetic Diseases, Inborn (158) · Cardiovascular Diseases (146)
Temozolomide (22) · Sodium Chloride (16) · Saline Solution (14) · Bevacizumab (11) · Radiotherapy (11) · Pregabalin (8) · Rituximab (8) · Cannabidiol (7) · Cyclophosphamide (7) · Donepezil (7) · Capecitabine (6) · Etoposide (6) · Sunitinib (6) · pasireotide (6) · Carboplatin (5)
Novartis Pharmaceuticals (32) · Pfizer (26) · Merck Sharp & Dohme LLC (16) · National Cancer Institute (NCI) (15) · GlaxoSmithKline (14) · M.D. Anderson Cancer Center (11) · Biogen (10) · Johns Hopkins University (9) · Washington University School of Medicine (8) · BioMarin Pharmaceutical (7) · Charite University, Berlin, Germany (7) · Eisai Inc. (7) · Massachusetts General Hospital (7) · Alexion Pharmaceuticals, Inc. (6) · AstraZeneca (6)
United States (700) · Canada (159) · United Kingdom (140) · Germany (137) · France (128) · Spain (116) · Italy (98) · Australia (76) · Belgium (68) · Netherlands (65) · Poland (63) · Japan (41) · Denmark (37) · Sweden (36) · Israel (32)
PMID 26112278, PMID 29480210, PMID 32250312, PMID 32522498, PMID 33675631, PMID 38010108, PMID 40603145, PMID 12411660, PMID 12542793, PMID 12749708, PMID 14615449, PMID 15014939, PMID 15791633, PMID 15864738, PMID 16648043, PMID 16673051, PMID 16899778, PMID 17143244, PMID 17188664, PMID 17293590, PMID 17438255, PMID 17470830, PMID 17653259, PMID 17881719, PMID 18234750, PMID 18413464, PMID 18418368, PMID 18425516, PMID 18425621, PMID 18447671, PMID 18797818, PMID 19092106, PMID 19654233, PMID 20042969, PMID 20185783, PMID 20297950, PMID 20363190, PMID 20571524, PMID 20634684, PMID 21356040, PMID 21419704, PMID 21428760, PMID 21468088, PMID 21565557, PMID 21586746, PMID 21700934, PMID 21784661, PMID 21799479, PMID 21865400, PMID 21873264
2016 (17), 2017 (15), 2015 (14), 2009 (12), 2014 (12), 2018 (11), 2008 (10), 2019 (10), 2023 (7), 2005 (5), N01NS42361 (2), P30CA033572 (2), P50NS044148 (2), R01CA137488 (2), R01NS034608 (2)